Investors including Nan Fung and Tekla Capital have increased the ophthalmic treatment developer's series B round to $35.9m, following a Novartis-led tranche a year ago.

Switzerland-based ophthalmic therapy developer Oculis increased a series B round featuring Nan Fung Life Sciences, a subsidiary of property developer Nan Fung, to CHF35.5m ($35.9m) on Friday. The company added CHF15.5m from investors including Nan Fung Life Sciences, investment adviser Tekla Capital Management and undisclosed existing investors to a CHF20m first tranche that closed in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.